📣 VC round data is live. Check it out!

Applied BioCode Valuation Multiples

Discover revenue and EBITDA valuation multiples for Applied BioCode and similar public comparables like Spectral AI, Xtant Medical, BioStem Technologies, Cyclopharm and more.

Applied BioCode Overview

About Applied BioCode

Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.


Founded

2016

HQ

United States

Employees

N/A

Financials (FY)

Revenue: $15M
EBITDA: ($5M)

EV

$58M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Applied BioCode Financials

Applied BioCode reported last fiscal year revenue of $15M and negative EBITDA of ($5M).

In the same fiscal year, Applied BioCode generated $8M in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).


Applied BioCode P&L

In the most recent fiscal year, Applied BioCode reported revenue of $15M and EBITDA of ($5M).

Applied BioCode is unprofitable as of last fiscal year, with gross margin of 55%, EBITDA margin of (30%), and net margin of (42%).

See analyst estimates for Applied BioCode
Last FY202320242025202620272028
Revenue$15M$13M$11M$15M
Gross Profit$8M$9M$7M$8M
Gross Margin55%68%59%55%
EBITDA($5M)($3M)($6M)($5M)
EBITDA Margin(30%)(25%)(58%)(30%)
EBIT Margin(47%)(47%)(81%)(47%)
Net Profit($6M)($5M)($8M)($6M)
Net Margin(42%)(42%)(76%)(42%)

Financial data powered by Morningstar, Inc.

Applied BioCode Stock Performance

Applied BioCode has current market cap of $75M, and enterprise value of $58M.

Market Cap Evolution


Applied BioCode's stock price is $0.73.

Applied BioCode share price increased by 6.9% in the last 30 days, and by 8.6% in the last year.

Applied BioCode has an EPS (earnings per share) of $-0.06.

See more trading valuation data for Applied BioCode
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$58M$75M0.9%6.9%-9.4%8.6%$-0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Applied BioCode Valuation Multiples

Applied BioCode trades at 3.8x EV/Revenue multiple, and (12.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for Applied BioCode

Applied BioCode Financial Valuation Multiples

As of May 12, 2026, Applied BioCode has market cap of $75M and EV of $58M.

Applied BioCode has a P/E ratio of (11.6x).

Last FY202320242025202620272028
EV/Revenue3.8x4.6x5.3x3.8x
EV/EBITDA(12.7x)(18.5x)(9.2x)(12.7x)
EV/EBIT(8.2x)(9.8x)(6.6x)(8.2x)
EV/Gross Profit7.0x6.8x8.9x7.0x
P/E(11.6x)(14.2x)(8.9x)(11.6x)
EV/FCF(7.7x)(8.6x)(8.5x)(7.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Applied BioCode Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Applied BioCode Margins & Growth Rates

In the most recent fiscal year, Applied BioCode reported gross margin of 55%, EBITDA margin of (30%), and net margin of (42%).

See estimated margins and future growth rates for Applied BioCode

Applied BioCode Margins

Last FY20242025202720282029
Gross Margin55%59%55%
EBITDA Margin(30%)(58%)(30%)
EBIT Margin(47%)(81%)(47%)
Net Margin(42%)(76%)(42%)
FCF Margin(50%)(63%)(50%)

Applied BioCode Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(13%)39%
Gross Profit Growth(24%)28%
EBITDA Growth101%(28%)
EBIT Growth49%(20%)
Net Profit Growth59%(23%)
FCF Growth2%9%

Data powered by FactSet, Inc. and Morningstar, Inc.

Applied BioCode Operational KPIs

Access forward-looking KPIs for Applied BioCode
Last FY202320242025202620272028
S&M Expenses to Revenue17%23%27%17%
G&A Expenses to Revenue22%30%34%22%
R&D Expenses to Revenue63%62%79%63%
Opex to Revenue102%115%140%102%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Applied BioCode Competitors

Applied BioCode competitors include Spectral AI, Xtant Medical, BioStem Technologies, Cyclopharm, Meta Biomed, Anatolia Geneworks, Creo Medical Group, LENSAR, Senzime and Nexstim.

Most Applied BioCode public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech, DeepTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Spectral AI3.5x3.6x(15.2x)
Xtant Medical0.6x0.7x5.3x7.6x
BioStem Technologies0.2x1.1x1.7x
Cyclopharm3.4x3.2x(6.7x)(6.6x)
Meta Biomed1.1x5.6x
Anatolia Geneworks4.9x(36.0x)
Creo Medical Group8.9x4.9x(1.6x)(2.8x)
LENSAR1.0x1.2x298.8x(94.6x)

This data is available for Pro users. Sign up to see all Applied BioCode competitors and their valuation data.

Start Free Trial

Applied BioCode Funding History

Before going public, Applied BioCode raised $9M in total equity funding, across 1 round.


Applied BioCode Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-16Series A$9MApplied BioCode is a molecular diagnostics company specializing in multiplexed pathogen detection panels and barcoded magnetic bead technology for infectious disease testing. The company developed the Biocode platform, which includes automated analyzers and reagent kits for gastrointestinal and respiratory pathogen detection. By 2023, Applied BioCode had grown revenue to NT$395.169 million, with growth driven primarily by its Enteritis Multiplex Molecular Detection Reagent product line and barcoded magnetic beads technology. The company has secured regulatory clearances including FDA Emergency Use Authorizations for COVID-19 testing panels and FDA 510(k) clearances for its molecular diagnostic systems and panels, positioning it in the competitive molecular diagnostics market alongside established players in infectious disease detection.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Applied BioCode

When was Applied BioCode founded?Applied BioCode was founded in 2016.
Where is Applied BioCode headquartered?Applied BioCode is headquartered in United States.
Is Applied BioCode publicly listed?Yes, Applied BioCode is a public company listed on Taiwan Stock Exchange.
What is the stock symbol of Applied BioCode?Applied BioCode trades under 6598 ticker.
When did Applied BioCode go public?Applied BioCode went public in 2017.
Who are competitors of Applied BioCode?Applied BioCode main competitors include Spectral AI, Xtant Medical, BioStem Technologies, Cyclopharm, Meta Biomed, Anatolia Geneworks, Creo Medical Group, LENSAR, Senzime, Nexstim.
What is the current market cap of Applied BioCode?Applied BioCode's current market cap is $75M.
What is the current revenue of Applied BioCode?Applied BioCode's last fiscal year revenue is $15M.
What is the current EV/Revenue multiple of Applied BioCode?Current revenue multiple of Applied BioCode is 3.8x.
Is Applied BioCode profitable?No, Applied BioCode is not profitable.
How many companies Applied BioCode has acquired to date?Applied BioCode hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Applied BioCode has invested to date?Applied BioCode hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Applied BioCode

Lists including Applied BioCode

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial